The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial.

Compared with placebo‐only, body weight was lower across individual time points and follow‐up collectively in both of the empagliflozin groups, except in the empagliflozin‐only group at 24 weeks (which did not reach statistical significance after correction for multiple comparisons).

also in 111,027 other papers